Nightstar Therapeutics (NASDAQ:NITE) – Investment analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for Nightstar Therapeutics in a research note issued on Tuesday, April 3rd. Jefferies Group analyst M. Yee expects that the company will earn ($0.48) per share for the quarter. Jefferies Group also issued estimates for Nightstar Therapeutics’ Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.55) EPS and Q4 2018 earnings at ($0.58) EPS.
Other research analysts also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Nightstar Therapeutics in a research report on Thursday. Chardan Capital started coverage on shares of Nightstar Therapeutics in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Mizuho reissued a “buy” rating and set a $20.00 target price on shares of Nightstar Therapeutics in a research report on Thursday. Six investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $28.50.
Shares of Nightstar Therapeutics stock opened at $11.70 on Thursday. Nightstar Therapeutics has a 52-week low of $10.01 and a 52-week high of $24.93. The company has a market capitalization of $346.47 and a PE ratio of -7.18.
A number of large investors have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC purchased a new stake in Nightstar Therapeutics during the 4th quarter worth approximately $1,771,000. Alyeska Investment Group L.P. purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $1,920,000. Citadel Advisors LLC purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $240,000. Ameriprise Financial Inc. purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $5,761,000. Finally, Nationwide Fund Advisors purchased a new stake in Nightstar Therapeutics during the 3rd quarter worth approximately $1,196,000. 29.06% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Jefferies Group Comments on Nightstar Therapeutics’ Q1 2018 Earnings (NITE)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/jefferies-group-comments-on-nightstar-therapeutics-q1-2018-earnings-nite.html.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.